Table 4.
Modalities that initially indicated abnormalities in asymptomatic PDAC.
| Initial modalities | Number (%) |
|---|---|
| Follow-up/work-up for other diseases | 109 |
| CT | 45 (41.3) |
| US | 27 (24.8) |
| MRI | 10 (9.2) |
| PET/CT | 8 (7.3) |
| EUS | 3 (2.8) |
| Blood tests | 16 (14.7) |
| Elevated tumor markers | 12 |
| Elevated liver enzymes | 3 |
| Elevated pancreatic enzymes | 1 |
| New-onset or exacerbation of DM | 61 |
| CT | 30 (49.2) |
| US | 20 (32.8) |
| MRI | 2 (3.3) |
| Blood tests | 9 (14.8) |
| Elevated tumor markers | 9 |
| Medical check-up | 35 |
| US | 24 (68.6) |
| CT | 1 (2.9) |
| MRI | 1 (2.9) |
| PET/CT | 1 (2.9) |
| Blood tests | 8 (22.9) |
| Elevated tumor markers | 4 |
| Elevated liver enzymes | 3 |
| Elevated pancreatic enzymes | 1 |
| All cases | 205 |
| CT | 76 (37.1) |
| US | 71 (34.6) |
| MRI | 13 (6.3) |
| PET/CT | 9 (4.4) |
| EUS | 3 (1.5) |
| Blood tests | 33 (16.1) |
| Elevated tumor markers | 25 |
| Elevated liver enzymes | 6 |
| Elevated pancreatic enzymes | 2 |
CT computed tomography, US ultrasonography, MRI magnetic resonance imaging, PET positron emission tomography, EUS endoscopic ultrasonography.